KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions. PMID 39523547 · Clin Infect Dis · 2025-Apr-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. PMID 40361957 · Diagnostics (Basel) · 2025-Apr-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19. PMID 39475087 · Am J Health Syst Pharm · 2025-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A core outcome set for acute otitis media (COS-AOM) for primary and community care studies. PMID 40296004 · BMC Prim Care · 2025-Apr-28 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. PMID 40295143 · J Immunother Cancer · 2025-Apr-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The safety and efficacy of a single dose of oral azithromycin given in labour to prevent skin and soft tissue infections in young infants in Fiji: a randomised controlled trial. PMID 40289086 · BMC Med · 2025-Apr-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. PMID 39607831 · Br J Dermatol · 2025-Apr-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial. PMID 40288803 · BMJ Open · 2025-Apr-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6-35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. PMID 40432079 · Vaccines (Basel) · 2025-Apr-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. PMID 40042578 · Jpn J Clin Oncol · 2025-Apr-26 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors. PMID 39987488 · Jpn J Clin Oncol · 2025-Apr-26 This is a record of a clinical trial protocol describing the study design, aims, and endpoints, but it does not report the results of the trial. While the study is randomized, involves chemotherapy, and has overall survival as a primary endpoint, the phase is not explicitly stated in the metadata, and the record is a protocol without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Continuous Intraoperative Dexmedetomidine on Interleukin-6 and Other Inflammatory Markers After Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial. PMID 40428745 · Medicina (Kaunas) · 2025-Apr-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparison of the inflammatory biomarkers IL- 6, TNF-α, and CRP to predict the effect of nutritional therapy on mortality in medical patients at risk of malnutrition : A secondary analysis of the randomized clinical trial EFFORT. PMID 40275239 · J Inflamm (Lond) · 2025-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial. PMID 40275195 · BMC Cancer · 2025-Apr-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial. PMID 40274842 · Sci Rep · 2025-Apr-24 The study is a secondary analysis of biomarkers in a COVID-19 randomized trial. It is not oncology, does not test a drug intervention, and is not a primary result report for a therapeutic agent, despite having time-to-event endpoints and Phase III randomization.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza. PMID 40267424 · N Engl J Med · 2025-Apr-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. PMID 40267423 · N Engl J Med · 2025-Apr-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria. PMID 40274305 · RMD Open · 2025-Apr-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy. PMID 40274284 · J Immunother Cancer · 2025-Apr-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early administration of vitamin C in patients with sepsis or septic shock in emergency departments: a multicenter, double-blind, randomized controlled trial: the C-EASIE trial. PMID 40269974 · Crit Care · 2025-Apr-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Visualizing a marker's degrees of necessity and of sufficiency in the predictiveness curve. PMID 40269760 · BMC Med Res Methodol · 2025-Apr-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial. PMID 40269252 · Commun Med (Lond) · 2025-Apr-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer]. PMID 40268551 · Zhonghua Zhong Liu Za Zhi · 2025-Apr-23 The study is a Phase III randomized oncology trial with a drug intervention, but its primary efficacy endpoint is a pharmacodynamic/biomarker outcome (hormone suppression), not a time-to-event clinical efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
mHealth Social Support Versus Standard Support for Diabetes Management in Safety-Net Emergency Department Patients: Randomized Phase-III Trial. PMID 40266665 · JMIR Diabetes · 2025-Apr-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Improvements Over Time with Valbenazine in Elderly Adults (≥65 Years) with Tardive Dyskinesia: Post Hoc Analyses of 2 Long-Term Studies. PMID 40265997 · J Clin Psychiatry · 2025-Apr-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis. PMID 40112274 · Neurology · 2025-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. PMID 40063041 · JAMA · 2025-Apr-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. PMID 39853273 · Blood Adv · 2025-Apr-22 The report is a secondary analysis of a Phase III randomized trial (ALPINE) in human oncology (CLL) with a drug intervention (zanubrutinib vs ibrutinib), but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Instead, it presents mutation data and resistance mechanisms, which is a secondary/biomarker analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. PMID 39808795 · Blood Adv · 2025-Apr-22 The report is a secondary/biomarker analysis within a Phase III trial. While it includes time-to-event data and HRs, the primary focus is on the prognostic impact of clonal hematopoiesis, not the reporting of the trial's primary or key secondary efficacy results for the drug intervention. Therefore, it does not meet the inclusion criteria for original formal-result reports of the randomized trial's efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies. PMID 39774762 · Blood Adv · 2025-Apr-22 The record describes a Phase III randomized trial of a drug (iptacopan) for paroxysmal nocturnal hemoglobinuria (an oncologic/hematologic malignancy). However, the abstract exclusively reports on patient-reported outcomes of fatigue and quality of life (using FACIT-Fatigue and EORTC QLQ-C30 questionnaires). It does not mention or provide any data on a time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, or a time-to-event analysis via Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the required criterion for a primary or key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. PMID 39808757 · J Clin Oncol · 2025-Apr-20 The study is a randomized, oncology trial in humans comparing two diagnostic/staging pathways (mpMRI vs. TURBT) for bladder cancer. It reports a time-to-event endpoint (Time to Correct Treatment). However, it is excluded because the intervention is non-drug (diagnostic/procedural), not a drug-containing therapy. The time-to-event endpoint is not a standard efficacy endpoint like OS or PFS but a process-of-care measure. No drug intervention is present.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. PMID 39668137 · J Clin Oncol · 2025-Apr-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. PMID 40284030 · Pharmaceuticals (Basel) · 2025-Apr-19 This is a real-world, non-randomized study (AENEID) evaluating IsaKd. While it reports time-to-event efficacy results (PFS, OS) for a drug regimen, it is not a randomized controlled trial and does not represent the original Phase III/IIIb trial results for the drug combination. The original Phase III trial (IKEMA) is referenced but is not the subject of this record.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old. PMID 40188565 · Vaccine · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. PMID 40158526 · Lancet · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. PMID 40158524 · Lancet · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. PMID 40081152 · Vaccine · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial. PMID 40251644 · J Transl Med · 2025-Apr-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients. PMID 40250846 · BMJ Open Respir Res · 2025-Apr-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of treating Helicobacter pylori infection on seizure frequency in children with drug-resistant idiopathic generalized epilepsy: a randomized controlled trial. PMID 40247384 · Ital J Pediatr · 2025-Apr-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer. PMID 40247218 · BMC Cancer · 2025-Apr-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of inclisiran based on background lipid-lowering treatment. PMID 40242982 · Eur J Prev Cardiol · 2025-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. PMID 39927615 · N Engl J Med · 2025-Apr-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-term outcomes of KangDuo surgical robot- versus Da Vinci surgical robot-assisted radical resection of colorectal cancer: a prospective cohort study. PMID 40241095 · BMC Surg · 2025-Apr-16 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial. PMID 40241061 · BMC Cancer · 2025-Apr-16 The study is an oncology randomized controlled trial with original results, but it is a physical rehabilitation program (non-drug only) and the primary endpoints are cardiorespiratory fitness and quality of life, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial. PMID 40240989 · BMC Cancer · 2025-Apr-16 This is an ancillary quality-of-life analysis of a Phase III RCT in chronic lymphocytic leukemia. While the parent trial is eligible for inclusion, this specific report focuses solely on HRQoL outcomes, which are excluded per the adjudication rules (non-efficacy endpoint). No time-to-event efficacy endpoint is reported or signaled in this abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Interventions to Reduce Serum Per- and Poly-Fluoroalkyl Substances Levels, Improve Cardiovascular Risk Profiles, and Improve Epigenetic Age Acceleration in US Firefighters: Protocol for Randomized Controlled Trial. PMID 40239196 · JMIR Res Protoc · 2025-Apr-16 The study is not an oncology trial; it is an occupational health intervention trial in firefighters focused on reducing PFAS levels and cardiovascular risk. It is a protocol for a randomized trial, not an original result report. The interventions (blood/plasma donation, physical activity, fasting) are non-pharmacologic. No time-to-event efficacy endpoint (OS, PFS, etc.) is described. The publication type is 'Clinical Trial Protocol'.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vaccines for preventing infections in adults with solid tumours. PMID 40237463 · Cochrane Database Syst Rev · 2025-Apr-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of early multidisciplinary team interventions on dietary management behavior in breast cancer patients: a pilot randomized controlled trial. PMID 40234862 · BMC Cancer · 2025-Apr-15 The study is a randomized oncology trial with a drug-containing intervention (chemotherapy), but it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis. PMID 40229815 · Eur J Med Res · 2025-Apr-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -